THYMOSIN ALPHA-1 10MG

Thymosin Alpha-1 (TA-1)

Thymosin Alpha-1, also known as TA-1 or Thymalfasin, is a naturally occurring 28-amino-acid peptide originally derived from the thymus gland. It plays a key role in regulating and supporting the immune system, particularly by influencing both the innate and adaptive immune responses.

TA-1 enhances the function of T cells, natural killer (NK) cells, and dendritic cells, while also balancing cytokine production. It’s known for helping the body respond more effectively to infections and immune challenges.

Mechanism of Action

Thymosin Alpha-1 works by stimulating immune cells, including T-helper and cytotoxic T cells, and enhancing the activity of natural killer cells. It also supports the maturation of dendritic cells, which are essential for antigen presentation and immune signaling.

TA-1 interacts with toll-like receptors (TLRs) on immune cells—particularly TLR2 and TLR9—to trigger immune activation. This process promotes a more balanced immune response, improving defense against infections while potentially reducing chronic inflammation.

Clinical and Research Applications

Chronic Hepatitis and Viral Infections

Thymosin Alpha-1 has been studied extensively in chronic hepatitis B and C. Clinical trials have shown that it can help reduce viral load and improve immune function, especially when used alongside other antiviral therapies such as interferon.

Sepsis and Critical Illness

In hospital and intensive care settings, Thymosin Alpha-1 has been used to help regulate immune responses in severe infections and sepsis. Some studies suggest that it may reduce disease severity and inflammation, and possibly lower mortality in specific patient groups.

COVID-19

During the COVID-19 pandemic, Thymosin Alpha-1 was researched for its ability to modulate immune response and reduce inflammation. While some studies showed potential benefits in older or critically ill patients, large-scale trials did not confirm a consistent reduction in mortality across all groups.

Cancer Support

Thymosin Alpha-1 has been explored as an immune-supportive therapy in various cancers, including lung and liver cancers. It may help enhance the immune system’s ability to recognize and target cancer cells and support patients undergoing chemotherapy or radiation by reducing immune suppression.

Immune Recovery and Deficiency

In individuals with weakened or suppressed immune systems—such as those with HIV or undergoing chemotherapy—TA-1 has been shown to improve immune parameters, increase T-cell counts, and support overall immune recovery.

Reported Benefits

• Enhances immune system efficiency and function
• Supports recovery from viral or bacterial infections
• May reduce inflammation and oxidative stress
• Promotes a stronger vaccine response
• Helps restore immune balance in immunocompromised individuals
• May reduce treatment side effects in cancer therapy

Safety and Side Effects

Thymosin Alpha-1 is generally well tolerated. The most common side effects are mild and include temporary redness, swelling, or soreness at the injection site. Some people may experience mild flu-like symptoms such as fatigue or low-grade fever.

Because it stimulates immune activity, caution is advised for individuals with autoimmune disorders or those receiving immunosuppressive therapy. Always consult a healthcare professional before use.

Regulatory Status

TA-1 is approved for clinical use in several countries under the brand name Zadaxin, primarily for viral hepatitis and immune modulation.

In the United States, it is not FDA-approved for any medical condition. However, it has received orphan drug status for certain rare conditions. Any use through compounding pharmacies is considered off-label and should be medically supervised.

Typical Administration

In research and clinical settings, Thymosin Alpha-1 is usually administered as a subcutaneous injection.

A common regimen for immune support in studies has been 1.6 mg twice weekly, although dosing and duration vary depending on the condition being treated and clinical goals

Summary

Thymosin Alpha-1 is a promising immunomodulatory peptide that has demonstrated benefits in a variety of immune-related conditions. It may help strengthen the immune system, improve resistance to infections, and enhance outcomes in specific medical treatments.

While international studies continue to explore its therapeutic potential, its use in the U.S. remains limited to research and off-label applications. Individuals interested in Thymosin Alpha-1 should discuss its potential benefits and risks with a qualified healthcare provider.

While TB-4 is not FDA-approved for human use outside of research, it continues to be studied for its promising applications in regenerative medicine and chronic inflammation management. Always consult a medical professional before using peptides or similar substances for health purposes. 

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.  These products are intended for research purposes only.